New treatments for COVID-19 and the ongoing opioid epidemic have expanded options for clinicians, but these therapies bring some unique toxicities that warrant vigilance, pharmacists said during the 2021 Critical Care Congress Virtual Event.
Multiple EUAs for COVID-19 Treatments
The rapid emergence of the COVID-19 pandemic led to several emergency use authorizations (EUAs) in 2020 for treatments, including hydroxychloroquine (revoked in June), remdesivir (Veklury, Gilead),